Four proprietary platforms – each engineered to fix a fundamental gap in delivery.
Bioavailability, format flexibility, transdermal targeting, and rapid onset – backed by international patents and human PK evidence.
Each platform – C3-CURA™, En-Infi™, VesiFuze™, ORAMELT™ – validated through in-vitro and human PK studies.
Augmented Absorption Technology
C3-CURA™
500× Higher Bioavailability
Transforms poorly soluble actives into highly absorbable formats with dramatically superior uptake.
100% Water Solubility
Breakthrough solubilization enabling clear, stable, fast-absorbing liquid and solid dosage forms.
Up to 1/100th Dose Reduction
Enhanced absorption allows for significantly lower dosing without compromising efficacy.
Backed by Human PK & Clinical Evidence
Demonstrated absorption, performance and safety across multiple clinical studies.
Patents
WO 2020/084634 A1 · SG Patent 11202103782S (Granted) · US 2022054580A1 (Notice of grant) · JP 7671693 · IN 201841039937 · AU 2019365596
Powers these ingredients
Nanotechnology for Vitamin D3 & Lipophilic Actives
En-Infi™
Stable Ultra-Nano Solutions (<50 nm)
Ensures uniform particle size, superior dispersion, and rapid absorption.
Enhanced Bioavailability
Optimized for Vitamin D3 and lipophilic botanicals with poor solubility.
Improved Clinical Performance
Faster onset and more consistent therapeutic outcomes than conventional formats.
Sugar-Free, Clear and Highly Stable
Ideal for pediatric, geriatric, and on-the-go liquid supplement formats.
Patents
Patent Application IN 202341043622
Powers these ingredients
Emulgel Transdermal Lipid Vesicular Delivery
VesiFuze™
Deep Transdermal Penetration
Deformable lipid vesicles bypass the stratum corneum and deliver actives directly to the target tissue.
Targeted Joint & Muscle Delivery
Reaches synovial fluid and inflamed regions for superior relief in arthritis, sports injuries and chronic pain.
Rapid, Localized Action
Rapid absorption with minimized systemic exposure and reduced side effects.
Clinically Backed Pain Relief
Supported by multicenter real-world data and physician-reported outcomes.
Patents
WO 2022/175856 A1
Powers these ingredients
Rapid Mouth-Melt Granules
ORAMELT™
Dissolves in 5–10 Seconds
Without water – instant, convenient dosing for any environment.
Superior Compliance
Ideal for diabetic, pediatric, geriatric, bedridden, and on-the-move populations.
Fine, Taste-Masked Particles
Smooth mouthfeel with optimized flavour masking and no bitterness.
High Absorption & Fast Onset
Bypasses traditional GI limitations through buccal, sublingual and oropharyngeal absorption.
Patents
IN 447286 – IN 202247040434 (Granted)
Powers these ingredients
One molecule. Many formats. A defensible portfolio.
See how Stabicon's hero ingredient strategy expands a single proven molecule across indications, dosage forms, and consumer segments.
Translate